Dupilumab: An emerging therapy in allergic fungal rhinosinusitis()

Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat. Patients with recurrent attacks of the disease despite surgical management can benefit from biologics as adjunct therapies. Dupilumab has shown promising endpoints in patients with chronic rhinosinusitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Bulkhi, Adeeb A., Mirza, Ahmad A., Aburiziza, Abdullah J., Marglani, Osama A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2022
Materias:
Full-length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023893/
https://www.ncbi.nlm.nih.gov/pubmed/35497650
http://dx.doi.org/10.1016/j.waojou.2022.100638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023893/
https://www.ncbi.nlm.nih.gov/pubmed/35497650
http://dx.doi.org/10.1016/j.waojou.2022.100638

Ejemplares similares